After bankruptcy filing, Purdue Pharma may not be off hook

An office building with cars in front of it
In this Sept. 12, 2019, file photo, cars pass Purdue Pharma headquarters in Stamford, Conn. The company, which makes OxyContin and other drugs, filed court papers in New York on Sunday, Sept. 15 seeking Chapter 11 bankruptcy protection.
Frank Franklin II | AP

Updated: 4:21 p.m. | Posted: 12:26 p.m.

Purdue Pharma filed for bankruptcy in the first step in a complex, multibillion-dollar plan by the maker of OxyContin to settle thousands of lawsuits brought against it by state and local governments over the nation's deadly opioid disaster.

The company and members of the Sackler family, which owns it, expressed sympathy but not responsibility.

"Like families across America, we have deep compassion for the victims of the opioid crisis," family members said in a statement, calling the settlement plan a "historic step towards providing critical resources that address a tragic public health situation."

But the bankruptcy filing, made late Sunday, may not get either the drugmaker or the Sacklers off the legal hook.

Create a More Connected Minnesota

MPR News is your trusted resource for the news you need. With your support, MPR News brings accessible, courageous journalism and authentic conversation to everyone - free of paywalls and barriers. Your gift makes a difference.

About half the states and lawyers representing at least 1,000 local governments have agreed to the tentative settlement, which the company says could be worth $10 billion to $12 billion over time and would include at least $3 billion from the Sacklers.

Under the settlement, the family would give up control of the company, and Purdue Pharma would be transformed into a sort of hybrid between a corporation and a charity. It would continue to sell opioids but its profits would be devoted to cleaning up the opioid mess and reimbursing state and local governments for the cost of the crisis that has killed more than 400,000 Americans in the past two decades.

But a number of the other states that are holding out have made it clear that they intend to object to the deal in bankruptcy court and seek to continue their lawsuits against members of the Sackler family.

“Purdue’s bankruptcy filing won’t stop me and many other states from holding them and the Sacklers accountable in every way we can for the death and destruction they caused in the opioid crisis,” Minnesota Attorney General Keith Ellison tweeted Monday. “We won’t let them escape justice. This ain’t over, not by a long shot.”

In all, the company is facing some 2,600 lawsuits, mostly from local governments.

It will be up to federal bankruptcy Judge Robert Drain in White Plains, New York, to decide whether to approve the settlement, and also whether those state lawsuits can continue. A court hearing on the bankruptcy plan is expected Tuesday.

For Purdue and the Sacklers, the effort revolves around getting more states to agree to the settlement, which could make approval more likely.

"We are hopeful that in time, those parties who are not yet supportive will ultimately shift their focus to the critical resources that the settlement provides to people and problems that need them," the families of late company owners Mortimer and Raymond Sackler said in their statement.

The Sacklers were listed by Forbes magazine in 2016 as one of the 20 wealthiest families in the U.S. In a court filing last week, the New York attorney general's office contended that the family had transferred $1 billion to itself through Swiss bank accounts and other means.

As some states agreed to the deal last week, others complained that it didn't hold the family or company sufficiently accountable for their roles in the crisis.

In court filings, the family and the company have pushed back against accusations that the company played a central role in causing the crisis by overselling the benefits of its powerful prescription painkillers and downplaying the addiction risk.

The company's drugs represent a small fraction of the prescription opioids shipped over the years — and most fatal overdoses have been linked to illegal opioids such as heroin and illicitly made fentanyl.

Steve Miller, chairman of Purdue's board of directors, said on a conference call with reporters that an admission of wrongdoing is not part of the deal.

He warned that as legal battles drag on, the company's costs grow, leaving less for the plaintiffs in lawsuits.

"The resumption of litigation would rapidly diminish all the resources of the company and would be lose-lose-lose all the way around," he said.

One likely result of the company's filing is that it will be removed from the first federal trial over the toll of opioids, scheduled to start Oct. 21 in Cleveland. Johnson & Johnson and its subsidiaries along with drug distributors and one pharmacy chain, Walgreens, remain as defendants.